ClinicalTrials.gg
CompletedNCT02515630Updated Jun 18, 2023Results posted

Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

A Phase 2 interventional study of MMB in Primary Myelofibrosis (PMF), Post-polycythemia Vera (Post-PV) Myelofibrosis and Postessential Thrombocythemia (Post-ET) Myelofibrosis, sponsored by Sierra Oncology LLC - a GSK company. Completed at 13 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-18.

Sponsored by Sierra Oncology LLC - a GSK company (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
41
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing momelotinib in Primary Myelofibrosis — 3 open to participants now, 4 under way, none of them phase 3. momelotinib · Primary Myelofibrosis.

Enrollment
11th of 12
41 · median 138
Started
2016
the only one that year
Phase 2
5 of 12
1 open now
Registered
7th of 12
by date
Lead sponsor
8 of 12
Sierra Oncology LLC - a GSK company

Among the 12 studies testing momelotinib in Primary Myelofibrosis, this one is the 11th largest by enrollment, is the only one that started in 2016, is one of 5 in phase 2, and was the 7th registered.

Primary Myelofibrosis

627 studies on the registry are indexed under Primary Myelofibrosis; 125 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

3 of the 12 studies testing momelotinib in Primary Myelofibrosis are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About momelotinib

momelotinib: first FDA approval 2023 (OJJAARA), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing momelotinib in Primary Myelofibrosis, or all of them as a file.
02

Study summary

This study will evaluate the transfusion independence response rate in transfusion-dependent adults with myelofibrosis after treatment with momelotinib (MMB).

03

Conditions studied

  • Primary Myelofibrosis (PMF)
  • Post-polycythemia Vera (Post-PV) Myelofibrosis
  • Postessential Thrombocythemia (Post-ET) Myelofibrosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Diagnosis of PMF or Post PV/ET-MF
  • Requires myelofibrosis therapy, in the opinion of the investigator
  • High risk OR intermediate-2 risk defined by dynamic international prognostic scoring system (DIPSS) OR intermediate-1 risk defined by DIPSS and associated with symptomatic splenomegaly and/or hepatomegaly
  • Transfusion dependent at baseline, defined as ≥ 4 U red blood cell (RBC) transfusion in the 8 weeks prior to first dose of MMB
  • Acceptable organ function as evidenced by the following:

    • Count ≥ 50 x 10\^9/L
    • (AST/SGOT) and alanine aminotransferase (ALT/SGPT) ≤ 3 x (ULN) or AST or ALT ≤ 5 x ULN if liver is involved by disease process as judged by the investigator
    • Serum creatinine ≤ 2.0 mg/dL or calculated of ≥ 60 mL/min
    • Direct ≤ 2.0 x ULN
  • of > 24 weeks
  • Males and females of who engage in heterosexual intercourse must agree to use protocol specified method(s) of
  • Lactating females must agree to discontinue nursing before MMB administration
  • Able to understand and willing to sign the form

Key Exclusion Criteria:

  • Prior splenectomy
  • Splenic irradiation within 3 months prior to the first dose of MMB
  • Prior treatment with MMB
  • Known positive status of (HIV)
  • Chronic active or acute viral hepatitis A, B, or C infection (testing required for and C), or hepatitis B or C carrier
  • Use of strong cytochrome P450 3A4 () inducer within 2 weeks prior to the first dose of MMB
  • Uncontrolled intercurrent illness per protocol
  • Treatment with a Janus kinase (JAK) inhibitor within 21 days of the planned first dose of MMB
  • Presence of peripheral neuropathy ≥ (CTCAE) Grade 2
  • Unwilling or unable to undergo a MRI per requirements in the study protocol
  • Unwilling to consent to genomics sampling

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Momelotinib

    MMB for 24 weeks (± 7 days)

    Drug: MMB

Interventions

  • DrugMMB

    Momelotinib (MMB) tablet administered orally once daily

    Also known as: GS-0387, CYT387

06

What researchers measure

Primary outcomes

  1. Transfusion Independence Response by Week 24

    The percentage of subjects who became transfusion independent for ≥ 12 weeks at any time on study. A subject was considered transfusion independent on study if no RBC transfusion occurred in any 12-week period during the 24-week treatment period.

    Time frame: From baseline to Week 24

Secondary outcomes

  1. Transfusion Response Rate by Week 24

    The percentage of subjects who became transfusion independent for ≥ 8 weeks, defined as no RBC transfusions for at least an 8-week period at any time on study.

    Time frame: From baseline to Week 24

  2. Splenic Response Rate at Week 24

    The percentage of subjects who achieved a ≥ 35% reduction in spleen volume from baseline as measured by MRI at Week 24.

    Time frame: Measured at Week 24

  3. Response Rate in Total Symptom Score (TSS) at Week 24

    The percentage of subjects achieving a ≥ 50% reduction from baseline in TSS at Week 24, as measured by the modified Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPNSAF TSS) diary. Total symptom score was assessed using the modified MPN-SAF TSS Version 2, an 8-item questionnaire developed to assess symptom burden and quality of life in patients with MPN. The modified MPN-SAF TSS contained 8 questions, 7 of which were summed to generate the score (the included questions related to tiredness, early satiety, abdominal discomfort, night sweats, itching, bone pain, and pain under the ribs on the left side). Each question is scored on a scale of 0-10, where higher numbers indicate more severe symptoms. For this study, the TSS scale ranges from 0 to 70. The questionnaire was completed daily on an electronic diary device.

    Time frame: Measured at Week 24

  4. Change in Markers of Iron Metabolism and Anemia - Change From Baseline in Hepcidin Daily Change

    Hepcidin daily change (in nM) was calculated as the predose value subtracted from the 6 hours postdose value at each study visit. Daily hepcidin change at the baseline visit was the difference between 2 values obtained 6 hours apart. No momelotinib was administered on that day.

    Time frame: At baseline, Day 1, Weeks 2, 4, 8, 12, 16, 20 and 24

  5. Change in Markers of Iron Metabolism and Anemia - Trough Hepcidin

    Median hepcidin at trough was assessed predose at each study visit.

    Time frame: At baseline, Day 1, Weeks 2, 4, 8, 12, 16, 20 and 24

  6. Change in Markers of Iron Metabolism and Anemia - Serum Iron

    Percent change from baseline in serum iron, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).

    Time frame: At Weeks 2, 4, 8, 12, 16, 20 and 24

  7. Change in Markers of Iron Metabolism and Anemia - Hemoglobin

    Percent change from baseline in hemoglobin, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).

    Time frame: At Weeks 2, 4, 8, 12, 16, 20 and 24

  8. Change in Markers of Iron Metabolism and Anemia - Total Iron Binding Capacity

    Percent change from baseline in total iron binding capacity, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).

    Time frame: At Weeks 2, 4, 8, 12, 16, 20 and 24

  9. Change in Markers of Iron Metabolism and Anemia - Reticulocytes

    Percent change from baseline in reticulocytes, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).

    Time frame: At Weeks 2, 4, 8, 12, 16, 20 and 24

  10. Change in Markers of Iron Metabolism and Anemia - Reticulocytes/Erythrocytes%

    Percent change from baseline in reticulocytes/erythrocytes%, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).

    Time frame: At Weeks 2, 4, 8, 12, 16, 20 and 24

  11. Change in Markers of Iron Metabolism and Anemia - Erythropoietin

    Percent change in erythropoietin at Weeks 8 and 20. The baseline erythropoietin value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).

    Time frame: At Weeks 8 and 20

  12. Change in Markers of Iron Metabolism and Anemia - Erythrocytes

    Percent change from baseline in erythrocytes, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).

    Time frame: At Weeks 2, 4, 8, 12, 16, 20 and 24

  13. Change in Markers of Iron Metabolism and Anemia - Hematocrit

    Percent change from baseline in hematocrit, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).

    Time frame: At Weeks 2, 4, 8, 12, 16, 20 and 24

  14. Change in Markers of Iron Metabolism and Anemia - Ferritin

    Percent change from baseline in ferritin, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).

    Time frame: At Weeks 2, 4, 8, 12, 16, 20 and 24

  15. Change in Markers of Iron Metabolism and Anemia - Soluble Transferrin Receptor

    Percent change from baseline in soluble transferrin receptor, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).

    Time frame: At Weeks 2, 4, 8, 12, 16, 20 and 24

  16. Change in Markers of Iron Metabolism and Anemia - Transferrin Saturation

    Percent change from baseline in transferrin saturation, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).

    Time frame: At Weeks 2, 4, 8, 12, 16, 20 and 24

  17. Change in Markers of Iron Metabolism and Anemia - Unsaturated Iron Binding Capacity

    Percent change from baseline in unsaturated iron binding capacity, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).

    Time frame: At Weeks 2, 4, 8, 12, 16, 20 and 24

  18. Change in Markers of Iron Metabolism and Anemia - Platelets

    Percent change from baseline in platelets, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).

    Time frame: At Weeks 2, 4, 8, 12, 16, 20 and 24

  19. Change in Markers of Iron Metabolism and Anemia - Leukocytes

    Percent change from baseline in leukocytes, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).

    Time frame: At Weeks 2, 4, 8, 12, 16, 20 and 24

  20. Change in Markers of Iron Metabolism and Anemia - Blasts

    Change from baseline in % blasts at Weeks 2 and 4. The baseline % blasts value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).

    Time frame: At Weeks 2 and 4

  21. Change in Liver Iron Content

    Percent change from baseline in liver iron content assessed by MRI. The baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).

    Time frame: Measured at Week 24

  22. Change in Pharmacodynamics Biomarker - pSTAT3

    Percent change in %pSTAT stimulated CD3+/4+ T cell at Day 1 (postdose), Week 4 and Week 24. The baseline value is defined as the last predose value from the baseline period prior to or on the date of first dose of momelotinib administration (Day 1 predose).

    Time frame: On Day 1 and at Weeks 4 and 24

  23. Change in Pharmacodynamics Biomarker - pSTAT3/tSTAT3 Ratio

    Percent change in %pSTAT/%tSTAT Stimulated CD3+/4+ T cell ratio at Day 1 (postdose), Week 4 and Week 24. The baseline value is defined as the last predose value from the baseline period prior to or on the date of first dose of momelotinib administration (Day 1 predose).

    Time frame: On Day 1 and at Weeks 4 and 24

  24. Change in Inflammatory Markers - C-Reactive Protein (CRP)

    Percent change in C-reactive protein at Weeks 2, 12 and 24. The baseline C-reactive protein value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).

    Time frame: At Weeks 2, 12 and 24

07

Results

Posted Jan 20, 2021
Limitations and caveats
Pharmacokinetics parameters were removed as an analysis endpoint in the SAP due to the sparse PK samples collection. Change in circulating cytokine and inflammatory markers were limited to CRP as an analysis endpoint in the SAP.

Participant flow

This study enrolled transfusion-dependent myelofibrosis patients at oncology centers in the United States and Canada. Following completion of the 24-week study period, patients who were benefiting had the option to continue maintenance momelotinib treatment in an open-label extension study (NCT02124746).

Participant flow — Overall Study
MilestoneMomelotinib (MMB)
Started41
Completed25
Not completed16
Withdrew: Withdrawal by subject5
Withdrew: Adverse event4
Withdrew: Physician decision4
Withdrew: Death2
Withdrew: Disease progression1

Outcome measures

PrimaryTransfusion Independence Response by Week 24

The percentage of subjects who became transfusion independent for ≥ 12 weeks at any time on study. A subject was considered transfusion independent on study if no RBC transfusion occurred in any 12-week period during the 24-week treatment period.

Time frame:
From baseline to Week 24
Reported as:
Number · percentage of subjects
Transfusion Independence Response by Week 24
percentage of subjectsTotal
Transfusion Independence Response by Week 2434.1 (22.0 to 48.1)
SecondaryTransfusion Response Rate by Week 24

The percentage of subjects who became transfusion independent for ≥ 8 weeks, defined as no RBC transfusions for at least an 8-week period at any time on study.

Time frame:
From baseline to Week 24
Reported as:
Number · percentage of subjects
Transfusion Response Rate by Week 24
percentage of subjectsTotal
Transfusion Response Rate by Week 2439.0 (26.2 to 53.1)
SecondarySplenic Response Rate at Week 24

The percentage of subjects who achieved a ≥ 35% reduction in spleen volume from baseline as measured by MRI at Week 24.

Time frame:
Measured at Week 24
Reported as:
Number · percentage of subjects
Splenic Response Rate at Week 24
percentage of subjectsTotal
Splenic Response Rate at Week 2412.2 (4.9 to 23.9)
SecondaryResponse Rate in Total Symptom Score (TSS) at Week 24

The percentage of subjects achieving a ≥ 50% reduction from baseline in TSS at Week 24, as measured by the modified Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPNSAF TSS) diary. Total symptom score was assessed using the modified MPN-SAF TSS Version 2, an 8-item questionnaire developed to assess symptom burden and quality of life in patients with MPN. The modified MPN-SAF TSS contained 8 questions, 7 of which were summed to generate the score (the included questions related to tiredness, early satiety, abdominal discomfort, night sweats, itching, bone pain, and pain under the ribs on the left side). Each question is scored on a scale of 0-10, where higher numbers indicate more severe symptoms. For this study, the TSS scale ranges from 0 to 70. The questionnaire was completed daily on an electronic diary device.

Time frame:
Measured at Week 24
Reported as:
Number · percentage of subjects
Response Rate in Total Symptom Score (TSS) at Week 24
percentage of subjectsTotal
Response Rate in Total Symptom Score (TSS) at Week 2415.8 (7.1 to 28.8)
SecondaryChange in Markers of Iron Metabolism and Anemia - Change From Baseline in Hepcidin Daily Change

Hepcidin daily change (in nM) was calculated as the predose value subtracted from the 6 hours postdose value at each study visit. Daily hepcidin change at the baseline visit was the difference between 2 values obtained 6 hours apart. No momelotinib was administered on that day.

Time frame:
At baseline, Day 1, Weeks 2, 4, 8, 12, 16, 20 and 24
Reported as:
Median · nM
Change in Markers of Iron Metabolism and Anemia - Change From Baseline in Hepcidin Daily Change
nMTransfusion Independence RespondersTransfusion Independence Non-RespondersTotal
Baseline-1.7 (-2.1 to 4.7)0.1 (-3.3 to 4.5)0.0 (-3.3 to 4.6)
Day 1-4.8 (-10.2 to -1.4)-11.2 (-16.0 to -5.8)-8.6 (-14.4 to -3.3)
Week 2-4.9 (-9.1 to -0.4)-6.7 (-11.3 to -1.2)-6.3 (-9.2 to -0.7)
Week 4-2.6 (-8.5 to 0.1)-7.4 (-9.6 to -0.9)-5.4 (-9.6 to 0.1)
Week 8-2.9 (-7.3 to -0.9)-5.2 (-17.7 to 2.1)-4.4 (-10.9 to -0.6)
Week 12-1.4 (-6.8 to 0.7)-5.7 (-8.7 to -0.9)-4.1 (-8.4 to 0.5)
Week 16-0.4 (-6.4 to 0.7)-4.3 (-15.1 to 1.9)-2.7 (-8.5 to 1.1)
Week 200.0 (-6.6 to 4.2)-7.8 (-12.5 to -1.9)-5.3 (-9.0 to 1.5)
Week 24-1.0 (-4.6 to 0.1)-1.8 (-7.8 to 0.1)-1.4 (-6.0 to 0.1)
SecondaryChange in Markers of Iron Metabolism and Anemia - Trough Hepcidin

Median hepcidin at trough was assessed predose at each study visit.

Time frame:
At baseline, Day 1, Weeks 2, 4, 8, 12, 16, 20 and 24
Reported as:
Median · nM
Change in Markers of Iron Metabolism and Anemia - Trough Hepcidin
nMTransfusion Independence RespondersTransfusion Independence Non-RespondersTotal
Baseline22.0 (9.6 to 33.9)42.4 (27.4 to 64.9)36.6 (18.6 to 48.5)
Day 119.7 (5.5 to 30.8)43.7 (29.9 to 58.7)36.5 (22.4 to 48.0)
Week 225.1 (14.6 to 29.7)52.1 (37.4 to 61.2)38.4 (25.8 to 57.6)
Week 419.8 (13.7 to 30.8)46.4 (39.1 to 57.1)37.6 (19.8 to 51.9)
Week 816.6 (10.1 to 29.2)51.7 (39.9 to 59.4)35.5 (16.9 to 52.7)
Week 1221.3 (10.9 to 30.4)44.7 (23.3 to 53.9)30.4 (15.6 to 44.8)
Week 1616.9 (7.1 to 29.0)51.9 (43.7 to 62.9)34.5 (17.1 to 51.9)
Week 2013.4 (4.5 to 27.4)44.2 (31.5 to 49.7)27.5 (13.4 to 44.3)
Week 2415.5 (4.9 to 28.8)51.5 (27.9 to 60.2)28.4 (14.2 to 45.2)
SecondaryChange in Markers of Iron Metabolism and Anemia - Serum Iron

Percent change from baseline in serum iron, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).

Time frame:
At Weeks 2, 4, 8, 12, 16, 20 and 24
Reported as:
Median · % Change from baseline
Change in Markers of Iron Metabolism and Anemia - Serum Iron
% Change from baselineTransfusion Independence RespondersTransfusion Independence Non-RespondersTotal
Week 24.5 (-14.6 to 73.2)5.9 (-10.3 to 31.0)5.9 (-11.8 to 39.6)
Week 439.8 (1.8 to 108.1)5.7 (-16.2 to 33.3)13.3 (-12.7 to 57.8)
Week 89.3 (-23.6 to 44.0)5.4 (-15.6 to 42.0)6.4 (-18.2 to 44.0)
Week 123.0 (-25.2 to 73.2)14.3 (3.1 to 35.1)12.8 (-7.9 to 39.4)
Week 16-15.5 (-20.3 to 56.6)16.5 (-19.3 to 30.7)8.9 (-19.4 to 30.7)
Week 20-11.1 (-17.8 to 41.7)9.9 (-7.4 to 28.1)1.9 (-17.8 to 34.6)
Week 24-8.1 (-20.4 to 45.1)-5.1 (-24.3 to 31.1)-6.6 (-22.9 to 37.4)
SecondaryChange in Markers of Iron Metabolism and Anemia - Hemoglobin

Percent change from baseline in hemoglobin, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).

Time frame:
At Weeks 2, 4, 8, 12, 16, 20 and 24
Reported as:
Median · % Change in from baseline
Change in Markers of Iron Metabolism and Anemia - Hemoglobin
% Change in from baselineTransfusion Independence RespondersTransfusion Independence Non-RespondersTotal
Week 212.8 (0.0 to 20.3)9.2 (0.0 to 26.3)9.9 (0.0 to 20.4)
Week 48.3 (1.4 to 15.9)6.3 (-1.2 to 20.6)6.9 (-1.2 to 20.6)
Week 812.4 (4.8 to 27.7)0.4 (-7.7 to 14.2)5.6 (-6.3 to 19.1)
Week 1215.6 (5.3 to 25.3)4.5 (-12.5 to 13.4)7.5 (-4.8 to 17.4)
Week 1612.3 (4.8 to 32.9)0.6 (-9.5 to 15.0)10.2 (-6.3 to 19.7)
Week 2013.1 (5.3 to 28.9)6.9 (-7.1 to 17.3)7.4 (-3.9 to 17.9)
Week 2410.0 (-2.1 to 29.4)5.8 (-1.3 to 14.4)7.9 (-1.4 to 17.6)
SecondaryChange in Markers of Iron Metabolism and Anemia - Total Iron Binding Capacity

Percent change from baseline in total iron binding capacity, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).

Time frame:
At Weeks 2, 4, 8, 12, 16, 20 and 24
Reported as:
Median · % Change from baseline
Change in Markers of Iron Metabolism and Anemia - Total Iron Binding Capacity
% Change from baselineTransfusion Independence RespondersTransfusion Independence Non-RespondersTotal
Week 24.5 (0.4 to 13.6)2.0 (-5.5 to 8.9)2.8 (-1.6 to 10.1)
Week 46.7 (-2.5 to 15.7)1.5 (-9.6 to 10.7)2.2 (-5.6 to 11.0)
Week 84.9 (-2.7 to 10.3)0.6 (-7.4 to 13.7)2.4 (-6.6 to 11.5)
Week 126.6 (-3.9 to 12.6)2.4 (-5.9 to 20.2)6.6 (-5.5 to 15.1)
Week 164.5 (-3.2 to 9.8)1.5 (-10.0 to 14.2)3.6 (-5.3 to 11.3)
Week 2015.5 (3.4 to 22.1)5.5 (-11.6 to 15.4)10.6 (1.6 to 17.2)
Week 247.3 (3.6 to 15.8)0.5 (-8.4 to 10.7)5.5 (-5.9 to 13.0)
SecondaryChange in Markers of Iron Metabolism and Anemia - Reticulocytes

Percent change from baseline in reticulocytes, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).

Time frame:
At Weeks 2, 4, 8, 12, 16, 20 and 24
Reported as:
Median · % Change from baseline
Change in Markers of Iron Metabolism and Anemia - Reticulocytes
% Change from baselineTransfusion Independence RespondersTransfusion Independence Non-RespondersTotal
Week 233.6 (-6.7 to 67.5)-9.6 (-26.0 to 26.4)2.9 (-23.6 to 36.2)
Week 411.8 (4.0 to 40.7)5.5 (-32.7 to 46.4)7.5 (-29.3 to 43.5)
Week 830.0 (13.2 to 35.0)-16.0 (-30.6 to 28.4)15.6 (-24.5 to 31.0)
Week 1215.8 (-6.3 to 45.1)-9.5 (-34.5 to 33.3)4.8 (-17.3 to 44.2)
Week 1631.2 (-22.1 to 58.5)8.8 (-24.0 to 35.5)18.3 (-23.1 to 45.6)
Week 2034.0 (-35.6 to 70.4)7.7 (-48.6 to 27.7)16.3 (-44.8 to 48.1)
Week 2429.9 (11.5 to 58.3)-0.6 (-32.0 to 67.8)24.1 (-12.0 to 58.4)
SecondaryChange in Markers of Iron Metabolism and Anemia - Reticulocytes/Erythrocytes%

Percent change from baseline in reticulocytes/erythrocytes%, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).

Time frame:
At Weeks 2, 4, 8, 12, 16, 20 and 24
Reported as:
Median · % Change from baseline
Change in Markers of Iron Metabolism and Anemia - Reticulocytes/Erythrocytes%
% Change from baselineTransfusion Independence RespondersTransfusion Independence Non-RespondersTotal
Week 230.0 (-16.7 to 42.6)-16.3 (-30.1 to 23.6)-8.0 (-28.1 to 36.4)
Week 48.2 (-7.0 to 20.4)1.5 (-36.3 to 29.6)4.1 (-29.9 to 26.5)
Week 812.4 (-5.6 to 33.3)-11.1 (-35.3 to 27.8)0.0 (-21.2 to 27.8)
Week 123.6 (-11.1 to 16.7)0.0 (-31.6 to 42.3)0.0 (-29.4 to 42.3)
Week 164.4 (-22.9 to 33.3)18.7 (-30.0 to 50.0)7.8 (-29.0 to 41.7)
Week 202.2 (-34.3 to 21.4)14.6 (-43.8 to 46.2)11.1 (-42.1 to 46.2)
Week 242.2 (-2.9 to 24.1)-7.8 (-34.2 to 72.6)-2.6 (-11.8 to 72.2)
SecondaryChange in Markers of Iron Metabolism and Anemia - Erythropoietin

Percent change in erythropoietin at Weeks 8 and 20. The baseline erythropoietin value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).

Time frame:
At Weeks 8 and 20
Reported as:
Median · % Change from baseline
Change in Markers of Iron Metabolism and Anemia - Erythropoietin
% Change from baselineTransfusion Independence RespondersTransfusion Independence Non-RespondersTotal
Week 8-30.8 (-55.6 to -6.8)-8.1 (-47.7 to 31.3)-24.5 (-55.4 to 29.4)
Week 20-45.0 (-63.4 to -2.0)8.5 (-16.2 to 82.9)-4.4 (-60.2 to 32.5)
SecondaryChange in Markers of Iron Metabolism and Anemia - Erythrocytes

Percent change from baseline in erythrocytes, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).

Time frame:
At Weeks 2, 4, 8, 12, 16, 20 and 24
Reported as:
Median · % Change from baseline
Change in Markers of Iron Metabolism and Anemia - Erythrocytes
% Change from baselineTransfusion Independence RespondersTransfusion Independence Non-RespondersTotal
Week 25.2 (0.0 to 20.0)3.4 (-6.1 to 12.1)3.4 (-6.1 to 16.7)
Week 46.7 (-8.8 to 13.3)3.6 (-3.6 to 21.5)3.8 (-3.7 to 16.0)
Week 83.6 (-2.0 to 23.3)0.0 (-13.1 to 13.0)3.0 (-6.1 to 22.9)
Week 123.1 (-3.6 to 26.7)3.6 (-13.8 to 11.4)3.4 (-10.0 to 23.1)
Week 160.0 (-8.8 to 26.7)-6.9 (-9.2 to 6.5)-2.9 (-8.8 to 12.0)
Week 20-3.3 (-12.0 to 26.7)-3.4 (-13.8 to 7.7)-3.4 (-12.1 to 12.2)
Week 24-8.0 (-9.7 to 26.7)3.3 (-7.1 to 11.4)0.0 (-9.7 to 19.2)
SecondaryChange in Markers of Iron Metabolism and Anemia - Hematocrit

Percent change from baseline in hematocrit, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).

Time frame:
At Weeks 2, 4, 8, 12, 16, 20 and 24
Reported as:
Median · % Change from baseline
Change in Markers of Iron Metabolism and Anemia - Hematocrit
% Change from baselineTransfusion Independence RespondersTransfusion Independence Non-RespondersTotal
Week 28.9 (-4.3 to 18.5)4.0 (-4.8 to 11.1)4.5 (-4.8 to 16.1)
Week 47.4 (-5.6 to 10.7)0.0 (-4.3 to 21.4)3.4 (-4.3 to 20.0)
Week 811.1 (3.6 to 25.9)-1.7 (-14.6 to 14.8)4.0 (-7.1 to 17.9)
Week 127.1 (-3.1 to 30.8)1.8 (-13.0 to 14.8)3.6 (-8.0 to 18.2)
Week 165.9 (-3.2 to 28.6)-4.2 (-8.3 to 8.2)3.8 (-7.7 to 10.7)
Week 207.1 (-3.2 to 26.9)0.0 (-12.0 to 4.3)0.0 (-7.9 to 12.8)
Week 248.0 (-3.6 to 28.6)2.3 (-9.1 to 9.1)4.5 (-8.3 to 14.8)
SecondaryChange in Markers of Iron Metabolism and Anemia - Ferritin

Percent change from baseline in ferritin, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).

Time frame:
At Weeks 2, 4, 8, 12, 16, 20 and 24
Reported as:
Median · % Change from baseline
Change in Markers of Iron Metabolism and Anemia - Ferritin
% Change from baselineTransfusion Independence RespondersTransfusion Independence Non-RespondersTotal
Week 211.6 (-11.2 to 35.9)8.8 (-0.2 to 25.3)8.8 (-7.4 to 31.0)
Week 419.1 (-6.8 to 32.9)8.3 (-3.5 to 38.8)13.6 (-3.8 to 35.3)
Week 84.0 (-24.1 to 15.9)30.4 (-5.6 to 38.7)16.7 (-10.1 to 32.5)
Week 12-0.6 (-11.2 to 11.3)26.4 (4.3 to 52.0)11.3 (-10.0 to 31.0)
Week 160.1 (-24.6 to 8.0)21.6 (0.7 to 100.9)6.7 (-8.7 to 30.9)
Week 203.5 (-42.9 to 23.1)13.6 (-10.0 to 74.6)7.0 (-33.6 to 61.8)
Week 24-14.2 (-40.2 to 6.6)15.4 (-20.7 to 59.7)1.4 (-27.2 to 42.6)
SecondaryChange in Markers of Iron Metabolism and Anemia - Soluble Transferrin Receptor

Percent change from baseline in soluble transferrin receptor, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).

Time frame:
At Weeks 2, 4, 8, 12, 16, 20 and 24
Reported as:
Median · % Change from baseline
Change in Markers of Iron Metabolism and Anemia - Soluble Transferrin Receptor
% Change from baselineTransfusion Independence RespondersTransfusion Independence Non-RespondersTotal
Week 24.0 (-14.7 to 18.1)-4.9 (-12.8 to 6.3)-4.8 (-14.1 to 16.7)
Week 4-1.4 (-7.0 to 26.2)8.8 (-16.6 to 31.5)0.7 (-16.6 to 30.9)
Week 86.7 (-15.3 to 24.0)11.0 (-15.1 to 37.2)7.4 (-15.3 to 28.4)
Week 120.8 (-18.3 to 13.5)11.1 (2.0 to 38.8)10.7 (-13.5 to 23.9)
Week 16-0.1 (-17.3 to 19.2)14.9 (-9.1 to 32.3)1.3 (-9.1 to 27.3)
Week 20-1.8 (-11.2 to 10.6)-0.7 (-7.4 to 21.2)-1.2 (-11.2 to 14.1)
Week 24-3.5 (-15.5 to 10.0)19.7 (-24.2 to 30.8)-1.8 (-16.7 to 26.1)
SecondaryChange in Markers of Iron Metabolism and Anemia - Transferrin Saturation

Percent change from baseline in transferrin saturation, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).

Time frame:
At Weeks 2, 4, 8, 12, 16, 20 and 24
Reported as:
Median · % Change from baseline
Change in Markers of Iron Metabolism and Anemia - Transferrin Saturation
% Change from baselineTransfusion Independence RespondersTransfusion Independence Non-RespondersTotal
Week 22.4 (-15.2 to 52.1)13.5 (-6.7 to 35.6)10.3 (-8.3 to 44.1)
Week 436.4 (4.2 to 75.0)9.7 (-17.2 to 36.7)10.5 (-4.8 to 45.8)
Week 89.5 (-21.7 to 33.3)-5.0 (-23.1 to 26.2)-3.1 (-22.4 to 29.7)
Week 1211.9 (-18.6 to 52.9)16.4 (-3.8 to 26.3)14.1 (-18.3 to 26.7)
Week 16-7.2 (-22.2 to 40.7)-13.5 (-24.6 to 33.3)-10.4 (-24.6 to 40.7)
Week 20-2.5 (-20.7 to 36.4)-20.8 (-40.4 to 8.3)-13.3 (-31.9 to 9.3)
Week 24-8.3 (-22.1 to 23.7)-20.8 (-31.7 to 25.0)-11.9 (-25.0 to 25.0)
SecondaryChange in Markers of Iron Metabolism and Anemia - Unsaturated Iron Binding Capacity

Percent change from baseline in unsaturated iron binding capacity, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).

Time frame:
At Weeks 2, 4, 8, 12, 16, 20 and 24
Reported as:
Median · % Change from baseline
Change in Markers of Iron Metabolism and Anemia - Unsaturated Iron Binding Capacity
% Change from baselineTransfusion Independence RespondersTransfusion Independence Non-RespondersTotal
Week 20.0 (-39.4 to 13.2)-5.1 (-31.1 to 14.6)0.0 (-31.5 to 13.2)
Week 4-4.0 (-24.3 to 1.9)0.0 (-35.7 to 34.0)-1.0 (-25.3 to 28.1)
Week 86.4 (-25.0 to 28.0)0.0 (-40.2 to 31.8)0.0 (-29.9 to 28.4)
Week 122.9 (-17.4 to 31.4)-18.4 (-33.6 to 7.0)-1.6 (-32.3 to 21.4)
Week 164.3 (-22.4 to 34.7)0.0 (-49.2 to 21.4)2.6 (-35.6 to 30.5)
Week 2016.5 (-12.0 to 62.8)5.1 (-39.8 to 44.0)14.2 (-15.9 to 46.7)
Week 2412.0 (2.5 to 32.2)6.9 (-35.7 to 64.9)12.0 (-11.3 to 64.9)
SecondaryChange in Markers of Iron Metabolism and Anemia - Platelets

Percent change from baseline in platelets, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).

Time frame:
At Weeks 2, 4, 8, 12, 16, 20 and 24
Reported as:
Median · % Change from baseline
Change in Markers of Iron Metabolism and Anemia - Platelets
% Change from baselineTransfusion Independence RespondersTransfusion Independence Non-RespondersTotal
Week 221.4 (-25.4 to 48.9)-24.4 (-41.8 to 6.3)-9.5 (-37.4 to 32.1)
Week 40.0 (-25.5 to 49.1)-29.7 (-43.7 to -4.1)-26.3 (-35.9 to 9.6)
Week 819.7 (-1.3 to 57.2)-33.6 (-48.2 to 3.3)-12.0 (-40.3 to 23.0)
Week 1224.1 (7.9 to 83.7)-27.7 (-49.0 to -11.5)-11.4 (-39.9 to 27.3)
Week 1617.8 (2.3 to 80.0)-26.1 (-48.0 to -6.2)-6.2 (-31.3 to 30.8)
Week 2031.0 (-6.9 to 41.4)-36.2 (-67.1 to -10.7)-14.3 (-37.8 to 34.3)
Week 2438.9 (-15.4 to 78.3)-22.5 (-52.1 to -8.8)-15.3 (-30.2 to 60.9)
SecondaryChange in Markers of Iron Metabolism and Anemia - Leukocytes

Percent change from baseline in leukocytes, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).

Time frame:
At Weeks 2, 4, 8, 12, 16, 20 and 24
Reported as:
Median · % Change from baseline
Change in Markers of Iron Metabolism and Anemia - Leukocytes
% Change from baselineTransfusion Independence RespondersTransfusion Independence Non-RespondersTotal
Week 211.6 (-10.0 to 42.9)-24.9 (-34.8 to 1.5)-14.9 (-29.8 to 11.4)
Week 46.8 (-18.3 to 38.6)-4.7 (-26.4 to 11.4)0.7 (-21.1 to 19.8)
Week 834.3 (11.6 to 57.1)-0.9 (-18.9 to 13.4)8.9 (-14.0 to 30.5)
Week 128.0 (5.4 to 48.4)-15.4 (-35.5 to 22.9)5.4 (-24.2 to 38.7)
Week 1642.0 (14.6 to 53.7)-6.7 (-26.9 to 27.0)15.2 (-14.3 to 45.7)
Week 2044.7 (13.0 to 70.5)-27.5 (-42.1 to 24.8)16.3 (-32.8 to 49.1)
Week 2453.0 (0.2 to 75.3)18.3 (-35.4 to 42.9)27.1 (-26.4 to 63.4)
SecondaryChange in Markers of Iron Metabolism and Anemia - Blasts

Change from baseline in % blasts at Weeks 2 and 4. The baseline % blasts value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).

Time frame:
At Weeks 2 and 4
Reported as:
Median · % Change from baseline
Change in Markers of Iron Metabolism and Anemia - Blasts
% Change from baselineTransfusion Independence RespondersTransfusion Independence Non-RespondersTotal
Week 20 (NA to NA)3.0 (3.0 to 3.0)3.0 (3.0 to 3.0)
Week 40 (NA to NA)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)
SecondaryChange in Liver Iron Content

Percent change from baseline in liver iron content assessed by MRI. The baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).

Time frame:
Measured at Week 24
Reported as:
Median · % Change from baseline
Change in Liver Iron Content
% Change from baselineTransfusion Independence RespondersTransfusion Independence Non-RespondersTotal
Change in Liver Iron Content4.7 (-18.4 to 25.0)53.3 (20.6 to 86.2)22.3 (-6.0 to 71.7)
SecondaryChange in Pharmacodynamics Biomarker - pSTAT3

Percent change in %pSTAT stimulated CD3+/4+ T cell at Day 1 (postdose), Week 4 and Week 24. The baseline value is defined as the last predose value from the baseline period prior to or on the date of first dose of momelotinib administration (Day 1 predose).

Time frame:
On Day 1 and at Weeks 4 and 24
Reported as:
Median · % Change from baseline
Change in Pharmacodynamics Biomarker - pSTAT3
% Change from baselineTransfusion Independence RespondersTransfusion Independence Non-RespondersTotal
Day 1 - 2 hours postdose-15.8 (-34.2 to -11.6)-13.5 (-24.4 to -7.6)-14.3 (-27.7 to -9.6)
Day 1 - 4 hours postdose-17.1 (-23.4 to -8.1)-10.6 (-30.6 to -2.4)-12.8 (-27.3 to -6.6)
Day 1 - 6 hours postdose-9.0 (-16.9 to -4.0)-4.3 (-16.9 to 0.3)-7.1 (-16.9 to -2.2)
Week 4 - predose-0.9 (-2.0 to 1.8)-2.9 (-5.5 to 17.7)-2.0 (-5.5 to 17.7)
Week 4 - 2 hours postdose-18.9 (-21.9 to -6.6)-20.0 (-25.7 to -7.4)-20.0 (-25.7 to -6.6)
Week 4 - 4 hours postdose-19.8 (-30.4 to -8.8)-14.1 (-28.7 to -6.1)-14.1 (-30.4 to -6.1)
Week 4 - 6 hours postdose-12.1 (-29.0 to -1.5)-9.1 (-12.9 to 4.9)-9.1 (-19.0 to 4.9)
Week 24 - predose-4.6 (-22.9 to 0.1)-0.3 (-7.9 to 5.1)-2.8 (-22.9 to 5.1)
Week 24 - 2 hours postdose-31.2 (-51.2 to -18.0)-10.7 (-28.4 to -10.1)-22.7 (-48.2 to -10.7)
Week 24 - 4 hours postdose-30.6 (-65.8 to -17.6)-14.4 (-22.6 to -12.9)-22.6 (-50.1 to -14.1)
Week 24 - 6 hours postdose-17.0 (-33.2 to -13.4)-10.1 (-10.2 to -4.9)-13.4 (-24.8 to -10.1)
SecondaryChange in Pharmacodynamics Biomarker - pSTAT3/tSTAT3 Ratio

Percent change in %pSTAT/%tSTAT Stimulated CD3+/4+ T cell ratio at Day 1 (postdose), Week 4 and Week 24. The baseline value is defined as the last predose value from the baseline period prior to or on the date of first dose of momelotinib administration (Day 1 predose).

Time frame:
On Day 1 and at Weeks 4 and 24
Reported as:
Median · % Change from baseline
Change in Pharmacodynamics Biomarker - pSTAT3/tSTAT3 Ratio
% Change from baselineTransfusion Independence RespondersTransfusion Independence Non-RespondersTotal
Day 1 - 2 hours postdose-13.2 (-38.9 to -11.5)-15.5 (-23.2 to 2.5)-13.4 (-26.3 to -3.2)
Day 1 - 4 hours postdose-9.6 (-23.2 to -0.5)-9.7 (-28.0 to -2.3)-9.7 (-23.9 to -2.3)
Day 1 - 6 hours postdose-9.1 (-17.2 to -5.7)-3.7 (-12.1 to 3.7)-4.6 (-13.7 to 1.7)
Week 4 - predose0.5 (-5.2 to 31.8)5.0 (-4.3 to 39.8)4.8 (-5.2 to 39.8)
Week 4 - 2 hours postdose-14.3 (-17.5 to 20.3)-9.1 (-22.6 to 9.6)-13.2 (-22.6 to 20.3)
Week 4 - 4 hours postdose3.0 (-32.9 to 118.3)-13.4 (-23.7 to 23.9)-13.4 (-31.5 to 38.1)
Week 4 - 6 hours postdose12.5 (-29.4 to 56.0)-6.1 (-17.1 to 32.8)-6.1 (-20.5 to 56.0)
Week 24 - predose-5.7 (-17.4 to -3.7)-3.5 (-8.8 to -2.8)-4.4 (-17.4 to -2.8)
Week 24 - 2 hours postdose-18.7 (-22.3 to -15.4)-7.6 (-22.1 to -2.6)-16.2 (-22.3 to -2.6)
Week 24 - 4 hours postdose-21.4 (-27.1 to -14.3)-11.5 (-15.4 to -9.6)-15.4 (-27.0 to -11.5)
Week 24 - 6 hours postdose-18.4 (-22.8 to -11.1)-6.5 (-9.0 to -5.1)-11.1 (-20.0 to -5.1)
SecondaryChange in Inflammatory Markers - C-Reactive Protein (CRP)

Percent change in C-reactive protein at Weeks 2, 12 and 24. The baseline C-reactive protein value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).

Time frame:
At Weeks 2, 12 and 24
Reported as:
Median · % Change from baseline
Change in Inflammatory Markers - C-Reactive Protein (CRP)
% Change from baselineTransfusion Independence RespondersTransfusion Independence Non-RespondersTotal
Week 2-68.7 (-75.6 to -43.5)-53.7 (-76.8 to -18.5)-55.6 (-76.3 to -29.5)
Week 12-67.8 (-73.1 to -28.2)-43.4 (-59.6 to 22.6)-48.9 (-70.1 to -15.6)
Week 24-59.8 (-79.1 to -44.8)-47.1 (-68.4 to 65.3)-54.8 (-73.8 to -30.7)

Adverse events

Collected over From the first dose of momelotinib until 30 days following the last dose.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Momelotinib (MMB)3/41 (7.3%)14/41 (34.1%)36/41 (87.8%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventMomelotinib (MMB)
AnemiaBlood and lymphatic system disorders3/41
Acute kidney injuryRenal and urinary disorders3/41
PresyncopeNervous system disorders2/41
Lung infectionInfections and infestations2/41
HypotensionVascular disorders2/41
NeutropeniaBlood and lymphatic system disorders1/41
DizzinessNervous system disorders1/41
Metabolic encephalopathyNervous system disorders1/41
AstheniaGeneral disorders1/41
DeathGeneral disorders1/41
Most frequent other events
Showing 10 of 26
Most frequent other events
EventMomelotinib (MMB)
CoughRespiratory, thoracic and mediastinal disorders12/41
DiarrhoeaGastrointestinal disorders10/41
NauseaGastrointestinal disorders9/41
FatigueGeneral disorders8/41
VomitingGastrointestinal disorders7/41
ThrombocytopeniaBlood and lymphatic system disorders7/41
PruritusSkin and subcutaneous tissue disorders7/41
Abdominal painGastrointestinal disorders6/41
DizzinessNervous system disorders6/41
HeadacheNervous system disorders6/41

Baseline characteristics

Age, Continuous
Age, Continuous(years)Transfusion Independence RespondersTransfusion Independence Non-RespondersTotal
Mean65 ± 10.072 ± 7.570 ± 9.0
Sex: Female, Male
Sex: Female, Male(Participants)Transfusion Independence RespondersTransfusion Independence Non-RespondersTotal
Female6915
Male81826
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Transfusion Independence RespondersTransfusion Independence Non-RespondersTotal
Black123
White112536
Not Permitted101
Other101
Spleen Volume
Spleen Volume(cm^3)Transfusion Independence RespondersTransfusion Independence Non-RespondersTotal
Mean2132.2 ± 1439.52018.1 ± 1248.52057.1 ± 1299.8
Total Symptom Score
Total Symptom Score(units on a scale)Transfusion Independence RespondersTransfusion Independence Non-RespondersTotal
Mean19.00 ± 16.1421.73 ± 13.9720.73 ± 14.65
RBC Units Transfused within 8 weeks prior to Enrollment
RBC Units Transfused within 8 weeks prior to Enrollment(Units of red blood cell)Transfusion Independence RespondersTransfusion Independence Non-RespondersTotal
Mean5 ± 1.97 ± 2.26 ± 2.3
Hepcidin
Hepcidin(nM)Transfusion Independence RespondersTransfusion Independence Non-RespondersTotal
Median22.0 (9.6 to 33.9)42.4 (27.4 to 64.9)36.6 (18.6 to 48.5)
Serum iron
Serum iron(ug/dL)Transfusion Independence RespondersTransfusion Independence Non-RespondersTotal
Median96.0 (56.0 to 123.0)127.0 (105.0 to 174.0)119.0 (84.0 to 165.0)

18 further baseline measures are reported on the registry.

08

Study locations

13 sites
  • Phoenix, Arizona, United States
  • Los Angeles, California, United States
  • Orange, California, United States
  • Jacksonville, Florida, United States
  • Baltimore, Maryland, United States
  • Ann Arbor, Michigan, United States
  • Saint Louis, Missouri, United States
  • Bronx, New York, United States
  • New York, New York, United States
  • Durham, North Carolina, United States
  • Cleveland, Ohio, United States
  • Houston, Texas, United States
  • Toronto, Ontario, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2016 to primary completion in Jul 2017, 17 months.

Results were first posted in Jan 2021, 3 years 6 months after primary completion. A results delay was requested in Jul 2018.

Of 30 industry-sponsored phase 2 interventional studies under Primary Myelofibrosis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 66. This study's 17 months is below that.

Counting every sponsor, half of 98 studies reached it within 66 months; a quarter within 32 and three quarters within 111.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2015
First posted
Aug 5, 2015
StartActual
Jan 29, 2016
Primary completionActual
Jul 18, 2017
CompletionActual
Aug 15, 2017
Results delay requested
Jul 2, 2018
Results first posted
Jan 20, 2021
Last update
Jun 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02515630
Responsible party
Sponsor
First posted
Aug 5, 2015
Start date
Jan 29, 2016
Primary completion
Jul 18, 2017
Completion
Aug 15, 2017
Results posted
Jan 20, 2021
Last update
Jun 18, 2023

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Momelotinib

Start the discussion